John Wrangle is an Oncology physician affiliated with Medical University of South Carolina. OpenAlex indexes 122 publications with 6,300 citations (h-index 26); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
171 Ashley Ave
Charleston, SC 294258908
Telephone
843-792-1414Registry record last updated 30 Jun 2014.
Clinical trials
- ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer
Sponsor: Medical University of South Carolina
- Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20231 payment
- E.R. Squibb & Sons, L.L.C.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
41.8%Phenothiazine41.8%Prochlorperazine Maleate100%Part D≥15 patientsMetabolism & gastrointestinal
32.7%Serotonin-3 Receptor Antagonist32.7%Ondansetron Hcl100%Part D≥13 patientsSensory organs
25.5%Corticosteroid25.5%Dexamethasone100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2019–2025 per NIH RePORTER. The latest:
- Exploiting Lineage-Specific Dependencies in Solid Tumors: Using Transcription Factors to Drive Therapeutic Effect In Situ
Medical University of South Carolina
FY2025$176,481R21CA288787 - Exploiting Lineage-Specific Dependencies in Solid Tumors: Using Transcription Factors to Drive Therapeutic Effect In Situ
Medical University of South Carolina
FY2024$211,778R21CA288787 - Lymphocyte and inflammatory cytokine markers of response in the first-in-human combination of anti-PD-1 mAb and IL-15/IL-15Ra complexes and investigation of mediators of anti-tumor immune responses
Medical University of South Carolina
FY2023$389,857R01CA222817
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Tanya Turan, MD
Medical University of South Carolina
Michael Zile, MD
Medical University of South Carolina
Don Rockey, MD
Medical University of South Carolina
Andrew Atz, MD
Medical University of South Carolina
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”